PRME
Prime Medicine, Inc.
1W: +2.8%
1M: -5.2%
3M: -1.9%
YTD: +2.8%
1Y: +78.8%
3Y: -71.9%
$3.64
+0.01 (+0.28%)
After Hours: $3.67 (+0.02, +0.69%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$7.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$655.4M
52W Range1.11-6.94
Volume2,252,198
Avg Volume3,005,408
Beta2.58
Dividend—
Analyst Ratings
Company Info
CEOAllan Reine
Employees214
SectorHealthcare
IndustryBiotechnology
IPO Date2022-10-20
Websiteprimemedicine.com
21 Erie Street
Cambridge, MA 02139
US
Cambridge, MA 02139
US
617-564-0013
About Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Latest News
HC Wainwright Lifts Earnings Estimates for Prime Medicine
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of “Moderate Buy” from Analysts
Lifesci Capital Weighs in on Prime Medicine FY2025 Earnings
Prime Medicine, Inc. $PRME Shares Acquired by ARK Investment Management LLC
Prime Medicine, Inc. $PRME Stock Position Increased by Amova Asset Management Americas Inc.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Reine Allan | A-Award | 1,300,000 | $4.38 | 2026-02-26 |
| LEE ANN L. | A-Award | 375,000 | $3.34 | 2026-02-23 |
| Alenson Carman | A-Award | 140,000 | $3.34 | 2026-02-23 |
| LEE ANN L. | A-Award | 180,995 | $4.04 | 2025-08-01 |
| LEE ANN L. | D-Return | 180,995 | $8.49 | 2025-08-01 |